Justin has a very active laboratory program focusing on biomarkers, clinical trials, gene regulation and new drug targets - notably kinases - in cancer.
Justin has a very active laboratory program focusing on biomarkers and clinical trials, new drug targets - notably kinases, and gene regulation. The kinases are new druggable targets and Justin leads an active drug development programme working on attacking these kinases. He runs an active programme investigating the role of non-coding RNAs in gene regulationn, including miRNAs and lncRNAs using the latest developments in sequencing technologies. With all of these projects, a large number of PhD students, physicians, technicians and post-doctoral scientists (often funded by Action Against Cancer, www.aacancer.org) are working tirelessly to understand the basic biology occurring here, which acts as a foundation for future work. A number of clinical trials are underway integrating the above, aiming to improve patient's quality and quantity of life.
Pregnancy-associated cancer
We are working to understand why some cancers occur in pregnancy and the hormonal changes that cause either existing mutations to accelerate, or whether new mutations can be induced. This involves a wide number of international collaborations and tissue collections utilising the latest next generation sequencing technologies.
Cell free DNA
We are understanding the role and diagnostic utility of cell free DNA in early breast cancer in particular, and mutations that occur within this.
Clinical trials
Justin is involved in a large number of clinical trials including immunotherapies and biosimilars. These are designed to improve quality and quantity of life and they use the latest biomarkers including cell free DNA.
Collaborators
Tom Powles, Silvia Montoto, Jeremy Steele, David Propper, Sarah Slater, Rebecca Bowem, Louise Jones, Barts
Mark Bower, Mark Nelson, Brian Gazzard, Frances Gotch, Steve Patterson, Chelsea and Westminster Hospital
Tim Crook, Breakthrough for breast cancer
Guiseppe Macino, University of Rome
Walter Messier, Evolutionary Genomics
Chris Benz, Buck Institute
Robert Clarke, Georgetown
David Hellmann, John Stone, Nancy Davidson, Vered Stearns, Majid Fotuhi, Johns Hopkins
David Kaplan, U Penn
Tufts, Liron Pantanowiz
Bruce Dezube, Harvard
Chris Wood, MD Anderson
Pramod Srivastava, University of Connecticut
Daniel Douek, NIH
Liron Pantanowicz, Tufts
Ornella Flore, NYU
Guest Lectures
Cancer Vaccine Consortium, Guest Lectures
Croom Lecturership, Royal College of Physicians of Edinburgh
Research Staff
Research Student Supervision
Dimitrov,G, Visualisation of cancer cell invasion
Harding,V, Estrogen receptor and long non coding RNAs
Jacob,J, MicroRNAs in breast and pancreatic cancer
Juskaite,V, Role of LMTK3 in invasion
Krell,J, p53 and miRNA induction
Lei Cheng,L, Signaling in cancer
Mato Prado,M, PhD student - MicroRNAs as bile-based biomarkers for pancreatic and biliary tract cancers
Stopka-Farooqui,U, Role of chemotherapeutics in inhibition of LMTK3 transfected cancer cells
castellano,L, MicroRNAs in cancer
filipovic,A, Nicastrin as a new target
frampton,A, MicroRNAs in pancreatic cancer
grothey,A, biology of cancer
koo,S, Biology of cancer and signaling
lombardo,Y, Mesothelin in mesothelioma
pellegrino,L, MicroRNAs in metastasis and motility
pinho,F, MicroRNAs and invasion
roca-alonso,L, MicroRNAs in heart failure
wood,D, LMTK3 in cancer
xu,Y, LMTK3 in cancer
zhang,H, KSR1 in cancer